{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:12:53Z","timestamp":1777497173863,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40256-019-00379-9","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T05:29:06Z","timestamp":1573709346000},"page":"239-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9424-8514","authenticated-orcid":false,"given":"Fadia Tohme","family":"Shaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7607-985X","authenticated-orcid":false,"given":"Krystal","family":"Sing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Milam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8778-9697","authenticated-orcid":false,"given":"Fasahath","family":"Husain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"del Aguila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3543-1420","authenticated-orcid":false,"given":"Miraj Y.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"issue":"29","key":"379_CR1","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315\u201381.","journal-title":"Eur Heart J."},{"issue":"13","key":"379_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.21037\/atm.2016.06.33","volume":"4","author":"F Sanchis-Gomar","year":"2016","unstructured":"Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016;4(13):256.","journal-title":"Ann Transl Med."},{"key":"379_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ahj.2017.01.016","volume":"187","author":"CN Hess","year":"2017","unstructured":"Hess CN, Clare RM, Neely ML, Tricoci P, Mahaffey KW, James SK, et al. Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. Am Heart J. 2017;187:194\u2013203.","journal-title":"Am Heart J."},{"issue":"19","key":"379_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","volume":"36","author":"T Jernberg","year":"2015","unstructured":"Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163\u201370.","journal-title":"Eur Heart J."},{"issue":"39","key":"379_CR5","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999\u20133058.","journal-title":"Eur Heart J."},{"issue":"12","key":"379_CR6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/clc.20356","volume":"31","author":"AA Motivala","year":"2008","unstructured":"Motivala AA, Tamhane U, Ramanath VS, Saab F, Montgomery DG, Fang J, et al. A prior myocardial infarction: how does it affect management and outcomes in recurrent acute coronary syndromes? Clin Cardiol. 2008;31(12):590\u20136.","journal-title":"Clin Cardiol."},{"issue":"1","key":"379_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"DM Lloyd-Jones","year":"2016","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, Writing Committee, et al. 2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92\u2013125.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"379_CR8","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation."},{"issue":"5","key":"379_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jacl.2016.06.011","volume":"10","author":"ND Wong","year":"2016","unstructured":"Wong ND, Young D, Zhao Y, Nguyen H, Caballes J, Khan I, et al. Prevalence of the American College of Cardiology\/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011\u20132012. J Clin Lipidol. 2016;10(5):1109\u201318.","journal-title":"J Clin Lipidol."},{"issue":"1","key":"379_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2217\/clp.12.88","volume":"8","author":"A Catapano","year":"2013","unstructured":"Catapano A, Toth PP, Tomassini JE, Tershakovec AM. The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. Clin Lipidol. 2013;8(1):13\u201341.","journal-title":"Clin Lipidol."},{"issue":"2","key":"379_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","volume":"223","author":"D Morrone","year":"2012","unstructured":"Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251\u201361.","journal-title":"Atherosclerosis."},{"issue":"25","key":"379_CR12","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med."},{"key":"379_CR13","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. 2011 [Updated March 2011]. http:\/\/handbook.cochrane.org\/. Accessed Apr 2018."},{"issue":"3","key":"379_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Soft. 2010;36(3):1\u201348.","journal-title":"J Stat Soft."},{"key":"379_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijcard.2015.08.103","volume":"201","author":"G Savarese","year":"2015","unstructured":"Savarese G, De Ferrari GM, Rosano GM, Perrone-Filardi P. Safety and efficacy of ezetimibe: a meta-analysis. Int J Cardiol. 2015;201:247\u201352.","journal-title":"Int J Cardiol."},{"issue":"1","key":"379_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/jep.12663","volume":"24","author":"Y Fei","year":"2018","unstructured":"Fei Y, Guyatt GH, Alexander PE, El Dib R, Siemieniuk RAC, Vandvik PO, et al. Addition of ezetimibe to statins for patients at high cardiovascular risk: systematic review of patient-important outcomes. J Eval Clin Pract. 2018;24(1):222\u201331.","journal-title":"J Eval Clin Pract."},{"issue":"4","key":"379_CR17","doi-asserted-by":"publisher","first-page":"e0124587","DOI":"10.1371\/journal.pone.0124587","volume":"10","author":"A Battaggia","year":"2015","unstructured":"Battaggia A, Donzelli A, Font M, Molteni D, Galvano A. Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015;10(4):e0124587.","journal-title":"PLoS One."},{"issue":"6","key":"379_CR18","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1185\/03007995.2011.571239","volume":"27","author":"DP Mikhailidis","year":"2011","unstructured":"Mikhailidis DP, Lawson RW, McCormick AL, Sibbring GC, Tershakovec AM, Davies GM, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin. 2011;27(6):1191\u2013210.","journal-title":"Curr Med Res Opin."},{"key":"379_CR19","doi-asserted-by":"publisher","first-page":"212534","DOI":"10.7573\/dic.212534","volume":"7","author":"M Vavlukis","year":"2018","unstructured":"Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs Context. 2018;7:212534.","journal-title":"Drugs Context."},{"issue":"1","key":"379_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12944-018-0880-8","volume":"17","author":"C Ai","year":"2018","unstructured":"Ai C, Zhang S, He Q, Shi J. Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse. Lipids Health Dis. 2018;17(1):239.","journal-title":"Lipids Health Dis."},{"issue":"29","key":"379_CR21","first-page":"2245","volume":"38","author":"U Landmesser","year":"2017","unstructured":"Landmesser U, Chapman MJ, Farnier M, Gencer B, Gielen S, Hovingh GK, et al. European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2017;38(29):2245\u201355.","journal-title":"Eur Heart J."},{"key":"379_CR22","doi-asserted-by":"crossref","unstructured":"Robinson JG, Jayanna MB, Brown AS, Aspry K, Orringer C, Gill EA, et al. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. J Clin Lipidol. 2019.","DOI":"10.1016\/j.jacl.2019.05.005"},{"issue":"22","key":"379_CR23","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med."},{"issue":"2","key":"379_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.clinthera.2017.12.018","volume":"40","author":"SJ Hong","year":"2018","unstructured":"Hong SJ, Jeong HS, Ahn JC, Cha DH, Won KH, Kim W, et al. A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) randomized controlled trial. Clin Ther. 2018;40(2):226\u201341.","journal-title":"Clin Ther"},{"issue":"2","key":"379_CR25","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.atherosclerosis.2015.03.004","volume":"240","author":"O Descamps","year":"2015","unstructured":"Descamps O, Tomassini JE, Lin J, Polis AB, Shah A, Brudi P, et al. Variability of the LDL-C lowering response to ezetimibe and ezetimibe\u2009+\u2009statin therapy in hypercholesterolemic patients. Atherosclerosis. 2015;240(2):482\u20139.","journal-title":"Atherosclerosis."},{"issue":"4","key":"379_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1185\/030079905X382004","volume":"21","author":"C Brohet","year":"2005","unstructured":"Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin. 2005;21(4):571\u20138.","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"379_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1253\/circj.CJ-17-0598","volume":"82","author":"K Hibi","year":"2018","unstructured":"Hibi K, Sonoda S, Kawasaki M, Otsuji Y, Murohara T, Ishii H, et al. Effects of ezetimibe-statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circ J. 2018;82(3):757\u201366.","journal-title":"Circ J."},{"issue":"12","key":"379_CR28","first-page":"OC28","volume":"11","author":"S Joshi","year":"2017","unstructured":"Joshi S, Sharma R, Rao HK, Narang U, Gupta N. Efficacy of combination therapy of rosuvastatin and ezetimibe vs rosuvastatin monotherapy on lipid profile of patients with coronary artery disease. J Clin Diagn Res. 2017;11(12):OC28\u201331.","journal-title":"J Clin Diagn Res"},{"issue":"3","key":"379_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1536\/ihj.14-311","volume":"56","author":"J Masuda","year":"2015","unstructured":"Masuda J, Tanigawa T, Yamada T, Nishimura Y, Sasou T, Nakata T, et al. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J. 2015;56(3):278\u201385.","journal-title":"Int Heart J."},{"key":"379_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijcard.2017.02.099","volume":"235","author":"D Ran","year":"2017","unstructured":"Ran D, Nie HJ, Gao YL, Deng SB, Du JL, Liu YJ, et al. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): ezetimibe and rosuvastatin versus high-dose rosuvastatin. Int J Cardiol. 2017;235:49\u201355.","journal-title":"Int J Cardiol."},{"issue":"5","key":"379_CR31","first-page":"4942","volume":"14","author":"Y Ren","year":"2017","unstructured":"Ren Y, Zhu H, Fan Z, Gao Y, Tian N. Comparison of the effect of rosuvastatin versus rosuvastatin\/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Exp Ther Med. 2017;14(5):4942\u201350.","journal-title":"Exp Ther Med."},{"issue":"11","key":"379_CR32","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1253\/circj.CJ-17-0193","volume":"81","author":"Y Ueda","year":"2017","unstructured":"Ueda Y, Hiro T, Hirayama A, Komatsu S, Matsuoka H, Takayama T, et al. Effect of ezetimibe on stabilization and regression of intracoronary plaque\u2014the ZIPANGU study. Circ J. 2017;81(11):1611\u20139.","journal-title":"Circ J."},{"issue":"5","key":"379_CR33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.23736\/S0392-9590.17.03818-4","volume":"36","author":"J Wang","year":"2017","unstructured":"Wang J, Ai XB, Wang F, Zou YW, Li L, Yi XL. Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. Int Angiol. 2017;36(5):467\u201373.","journal-title":"Int Angiol."},{"issue":"5","key":"379_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.hlc.2015.10.012","volume":"25","author":"X Wang","year":"2016","unstructured":"Wang X, Zhao X, Li L, Yao H, Jiang Y, Zhang J. Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart Lung Circ. 2016;25(5):459\u201365.","journal-title":"Heart Lung Circ."},{"issue":"1","key":"379_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2011.04.005","volume":"218","author":"AM West","year":"2011","unstructured":"West AM, Anderson JD, Meyer CH, Epstein FH, Wang H, Hagspiel KD, et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis. 2011;218(1):156\u201362.","journal-title":"Atherosclerosis."},{"issue":"S2","key":"379_CR36","first-page":"S328","volume":"64","author":"YC Zou","year":"2016","unstructured":"Zou YC. Effect of ezetimibe combined with low-dose atorvastatin calcium on carotid atherosclerosis in elderly patients with coronary heart disease. J Am Geriatr Soc. 2016;64(S2):S328.","journal-title":"J Am Geriatr Soc."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00379-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-019-00379-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00379-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T02:01:42Z","timestamp":1664935302000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-019-00379-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["379"],"URL":"https:\/\/doi.org\/10.1007\/s40256-019-00379-9","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"14 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This analysis was funded by Sanofi and Regeneron Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Fadia T. Shaya is Professor at the University of Maryland School of Pharmacy and has received consulting fees from Sanofi\/Regeneron for general advice on study design. Krystal Sing is an employee of and stockholder in Regeneron Pharmaceuticals, Inc. Robert Milam, Fasahath Husain, and Michael A. del Aguila are employees of Doctor Evidence, which was contracted by Sanofi\/Regeneron to participate in the design, conduct, and reporting of this study. Miraj Y. Patel is an employee of and stockholder in Sanofi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}